Dr. Ahmed Farhan
Millions of people now take drugs like Ozempic, Wegovy, and Mounjaro to manage diabetes or lose weight.
But a wave of new research is pointing to something almost nobody expected when these drugs first hit the market: they might also lower a person’s risk of addiction.
That’s a big claim. So let’s slow down and look at what the evidence actually shows — where it’s strong, where it’s shaky, and what it does and doesn’t mean if you or someone you know takes one of these medicines.
Why This Is Getting Attention Right Now
GLP-1 drugs have gone from a niche diabetes treatment to one of the most talked-about medicines in the world. Recent survey data suggests roughly 1 in 7 U.S. adults has now tried one, mostly for weight loss or blood sugar control.
At the same time, scientists have been quietly building a case that these drugs do more than curb appetite.
In March 2026, one of the largest studies yet on this question was published in The BMJ, a leading medical journal.
It pulled together health records from more than 600,000 people, making it the biggest look so far at whether GLP-1 drugs affect the risk of developing a substance use disorder — the medical term for when someone’s use of alcohol, nicotine, or other drugs becomes hard to control and starts to cause harm.
What the Latest Research Says
The BMJ study looked at U.S. military veterans with type 2 diabetes. Researchers compared two groups: people who started taking a GLP-1 drug, like semaglutide (Ozempic) or tirzepatide (Mounjaro), and people who started a different diabetes drug called an SGLT-2 inhibitor (a drug like empagliflozin, sold as Jardiance).
Comparing two diabetes drugs, instead of comparing a drug to nothing, matters. It means both groups were already managing their diabetes and seeing a doctor regularly.
That helps rule out the possibility that people on GLP-1 drugs simply had healthier habits or more medical attention overall — the difference between the groups should mainly come from the drug itself.
The researchers used a method called target trial emulation. In plain terms, that means they used real-world medical records to mimic what a randomized controlled trial would look like, since it wasn’t practical to randomly assign 600,000 real patients to different drugs.
It’s not as strong as a true randomized trial, but it’s a more careful approach than simply comparing two groups without accounting for how they were chosen.
What Researchers Actually Found
Among veterans with no prior history of substance problems, starting a GLP-1 drug was linked to about a 14% lower chance of developing a new substance use disorder over the next three years, compared with starting the SGLT-2 drug.
The drop showed up across several categories, including disorders related to alcohol, cannabis, and cocaine, with reductions in that same rough range for each.
Among veterans who already had a substance use disorder, the differences were even larger for serious, dangerous outcomes.
People who started a GLP-1 drug had notably fewer drug-related emergency room visits, fewer hospital stays, and far fewer overdoses over the follow-up period, along with fewer deaths related to substance use and fewer reports of suicidal thoughts.
This lines up with smaller studies that came before it. A separate clinical trial tested semaglutide directly against a placebo in people with alcohol use disorder.
It found that semaglutide reduced how much people drank on the days they did drink, and eased their cravings for alcohol, though it didn’t clearly reduce how many days a week they drank overall.
Another placebo-controlled trial, this one in people with both obesity and alcohol use disorder, tested a similar question with a similar design.
What It Means for Obesity, Diabetes, and Metabolic Health
For most people, this research doesn’t change why someone would start a GLP-1 drug in the first place — these are still primarily treatments for type 2 diabetes and obesity, and that’s where their strongest, best-proven benefits lie.
But it does reshape how scientists think about what these drugs actually do in the body. GLP-1 receptors sit not just in the gut and pancreas, but also in parts of the brain involved in reward, motivation, and craving.
That’s the same brain circuitry involved in why food, alcohol, nicotine, and other drugs can all feel rewarding. If a drug turns down the volume on that reward signal generally, it’s not a huge leap to think it might affect more than one kind of craving at once.
For doctors treating someone who has both diabetes or obesity and a history of heavy drinking or drug use, this research adds one more factor worth weighing when choosing between diabetes medications — not because GLP-1 drugs are an approved addiction treatment, but because an added benefit, if real, is worth knowing about.
Practical Implications
This is genuinely useful information, but it comes with real limits on what you should do with it.
If you’re on a GLP-1 drug already and also have a history of substance use, this research is worth mentioning to your doctor as part of your full picture — not because it changes your diabetes or weight-loss treatment, but because your doctor should know your full health history either way.
If you’re currently in treatment for a substance use disorder, this research is not a reason to change or stop that treatment. GLP-1 drugs are not an approved treatment for addiction, and proven treatments — including counseling and FDA-approved addiction medications — remain the standard of care.
What We Know
Multiple independent studies, using different methods and different patient groups, point in the same direction: GLP-1 drugs are associated with lower rates of substance use problems and safer outcomes for people who already have them.
There’s also a plausible explanation for why, rooted in how these drugs interact with the brain’s reward system, not just the gut.
What We Don’t Know
The largest study, the one from The BMJ, is what’s called an observational study. Even with careful statistical methods, it can show a strong association without fully proving the drug is the cause.
Some of the difference between groups could still come from factors researchers couldn’t fully measure or account for.
The clinical trial evidence — the kind that can more directly test cause and effect — is still early. It’s been done mainly for alcohol use disorder, involved relatively small numbers of people, and showed modest, mixed results rather than a dramatic effect.
Scientists don’t yet know the right dose for this purpose, which patients are most likely to benefit, or how long any effect lasts.
It’s also worth noting who was studied. The BMJ study looked mainly at older veterans, most of them men. The results may not apply equally to younger adults, women, or people outside the VA health system.
Common Misconceptions
“This means Ozempic cures addiction.” Not accurate. The effect sizes found so far are modest, and no GLP-1 drug is approved to treat addiction. This is an early, promising signal — not a cure.
“Doctors will start prescribing GLP-1 drugs for addiction now.” Not yet. Using a drug for a purpose it isn’t approved for is a decision made carefully, case by case, by a doctor — and larger trials are still needed before that becomes routine practice for addiction specifically.
“If it helps with alcohol cravings, it must work the same way for every substance.” Not necessarily. The evidence is strongest for alcohol so far. The mechanism may not affect every substance equally, and research on nicotine, opioids, and other drugs is still catching up.
Who Should Pay Particular Attention
People managing type 2 diabetes or obesity who also have a personal history of heavy drinking, smoking, or other substance use may want to bring this research up with their own doctor, simply as one more piece of their health picture.
People currently receiving treatment for a substance use disorder, or supporting a family member who is, should know that this research doesn’t change current best practices — it’s a developing area, not a settled one.
Practical, Evidence-Based Recommendations
Talk with your doctor about your full health history, including any past or current substance use, so that decisions about your medications — GLP-1 or otherwise — are made with the complete picture.
Don’t stop or change an existing addiction treatment plan based on this research. It isn’t designed to replace proven care.
If you’re curious whether a GLP-1 drug could be relevant to your own situation for reasons beyond diabetes or weight, that’s a conversation to have with a prescriber, not a decision to make on your own.
Keep in mind that this is a fast-moving area of research. Larger, more definitive clinical trials are already underway, and they should give a clearer answer in the next few years.
Frequently Asked Questions
Can I take Ozempic just to help with drinking or smoking?
No GLP-1 drug is currently approved for that purpose. These medications are approved for type 2 diabetes and weight management, and using one for a different purpose is a decision that belongs with a doctor, not something to pursue on your own.
Does this apply to every GLP-1 drug the same way?
Most of the research so far has focused on semaglutide (the active ingredient in Ozempic and Wegovy). Less is known about whether the effect is the same, stronger, or weaker with other GLP-1 drugs, like tirzepatide.
Is this proven to work?
Not yet, in the way that word usually gets used. The strongest evidence comes from a very large real-world study and one randomized trial focused on alcohol use disorder, both of which found real but modest effects. Larger, longer trials are still needed before this would be considered a proven treatment.
Why would a diabetes drug affect addiction at all?
GLP-1 receptors exist in parts of the brain tied to reward and craving, not just in the gut. That gives scientists a real, biological reason to think these drugs could affect more than food intake alone.
Should someone already in addiction treatment switch to a GLP-1 drug instead?
No. Established, FDA-approved treatments for substance use disorders remain the standard of care. Any change to an existing treatment plan should be made with a doctor, not based on this research alone.
Conclusion
The idea that a diabetes and weight-loss drug might also lower addiction risk sounds almost too tidy to be true.
But it’s backed by a growing, genuinely serious body of research — a very large real-world study, smaller randomized trials, and a plausible explanation for why it might happen in the brain.
At the same time, it’s not settled science, and it’s not a green light to use these drugs off-label for addiction.
For now, it’s a promising thread that researchers are actively pulling on. Whether it turns into an approved treatment down the road is something only bigger, longer trials will be able to answer.
References
Cai M, Choi T, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. The BMJ. 2026;392:e086886.
Qeadan F. Metabolic medicines and addiction: what GLP-1 receptor agonists might add to substance use care [editorial]. The BMJ. 2026;392:s325.
Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395-405.
SEMALCO trial investigators. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. The Lancet. 2026.
Wang W, Volkow ND, Berger NA, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024;15(1):4548.
Harvard Health Publishing. GLP-1 drugs may lower odds of developing substance use disorders. Harvard Medical School, 2026.
Gallup. In U.S., GLP-1 Usage Reaches New High. news.gallup.com, 2026.
